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Promiscuous antibodies characterised by their 
physico-chemical properties: from sequence to 
structure and back. 
Julie MJ Laffya*, Tihomir Dodevb*, Jamie A Macphersona , Catherine Townsendb, 
Hui Chun Lua , Deborah Dunn-Waltersb,c   & Franca Fraternalia+ 
 
ABSTRACT 
Human B cells produce antibodies, which bind to their cognate antigen based on 
distinct molecular properties of the antibody CDR loop. We have analysed a set 
of 10 antibodies showing a clear difference in their binding properties to a panel 
of antigens, resulting in two subsets of antibodies with a distinct binding 
phenotype. We call the observed binding multiplicity ‘promiscuous’ and selected 
physico-chemical CDRH3 characteristics and conformational preferences may 
characterise these promiscuous antibodies. To classify CDRH3 physico-chemical 
properties playing a role in their binding properties, we used statistical analyses 
of the sequences annotated by Kidera factors. To characterise structure-function 
requirements for antigen binding multiplicity we employed Molecular Modelling 
and Monte Carlo based coarse-grained simulations. The ability to predict the 
molecular causes of promiscuous, multi-binding behaviour would greatly 
improve the efficiency of the therapeutic antibody discovery process. 
* These authors contributed equally to the work 
+ Corresponding author 
a Randall Division of Cell and Molecular Biophysics, King’s College London UK 
b Department of Immunobiology, King’s College London UK  
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Keywords: Antibody CDRH3, binding promiscuity, conformational preferences, 
ELISA, Kidera Factors, Molecular Modelling, Monte Carlo simulations. 
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INTRODUCTION 
Immunoglobulins (Ig) are a crucial component of the adaptive immune response. 
Adaptive immunity is distinct from innate immunity in that it confers a highly 
specific defense against invading pathogens and is capable of creating memory 
against foreign molecules (antigens), enabling a rapid response upon repeated 
exposure to the same antigen. Immunoglobulins are produced by B cells and are 
either displayed on the cell surface, as B cell receptors, or are secreted into the 
extracellular environment and circulate as antibodies in the blood.  
Antigen recognition is mediated by the antibody variable regions, which are 
located at each of the two apical sites on the ‘Y’ arms of the antibody. A huge 
diversity of specificities in the antibody repertoire is achieved by gene 
rearrangement processes, whereby variable (V), diversity (D) and Joining (J) 
genes recombine to produce a complete heavy chain (VDJ) or light chain (VJ) 
variable gene. The rearranged gene is expressed in conjunction with a constant 
region that confers the functional attributes of the antibody.  The heavy chain 
and the light chain variable regions of the immunoglobulin protein fold to form a 
conserved β-sheet framework interspersed by six hypervariable loops or 
“complementarity determining regions” (CDRs), so-called because they come 
together to form the antigen-binding site. Amongst the CDRs (there are three 
from each chain), the third loop on the heavy chain (CDR-H3) is the most diverse 
because it is encoded by a stretch of nucleotides spanning all three IGHV-D-J 
gene segments. Similarly, the equivalent light chain region (CDR-L3) is also 
diverse although not to the same extent. Site-directed mutagenesis and loop 
grafting studies have shown that the H3 loop can be sufficient to define antibody 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
specificity (1). Crystal structure analyses have also identified the CDR-H3 region 
as being centrally positioned in the antigen-binding site, always in contact with 
antigen and, in some cases, able to change conformation upon binding (2). In 
fact, CDR-H3 is the only exception to the canonical structure model, which has 
identified all remaining CDRs as belonging to one of a few discrete 
conformations on the basis of sequence length and composition (3-6).  
A consequence of the random nature of the Ig gene rearrangement process is 
that a significant proportion of antibodies produced in the bone marrow may be 
autoreactive (7). Potentially dangerous autoreactive antibodies must be 
removed from the repertoire at tolerance checkpoints in the development 
process in order to avoid autoimmune diseases such as systemic lupus 
erythematosus (8) and rheumatoid arthritis (9). Some antibodies are capable of 
binding multiple chemically and structurally diverse antigens, which means that 
although an antibody may be produced with the potential to usefully bind to 
exogenous antigens, it may result in binding to self-antigens. Thus previous 
literature on tolerance and autoimmunity will quite often refer to 
“polyreactivity” of an antibody. Polyreactive antibodies occur in normal human 
sera and are thought to act as a first line of defense against foreign antigens (10). 
They have been shown to cause bacterial lysis (11, 12), induce complement and 
clear apoptotic cells (13). So in the case of polyreactive antibodies a trade-off 
balance between potentially useful initial activity and potentially harmful anti-
self effects has to be maintained. 
 
In the literature people refer indiscriminately to polyreactive and/or polyspecific 
antibodies and the definition intrinsic in the prefix ‘poly’ is matter of debate (14). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
It has been recently clarified that this term does not refer to the case of multiple 
binding due to some stickiness of the antibody chemico-physical properties and 
that a large screen over a panel of putative antigens is needed before extracting 
antibodies that clearly react specifically to a subset of these target antigens.  
Another term that is frequently used when referring to antibodies multi-binding 
behavior is promiscuity (15, 16). This term has long been investigated in the 
field of enzyme binding (17), and has been referred to as functional promiscuity, 
again implying some specific functional behavior resulting from the particular 
type of binding mode. It is claimed by Favia at al. (17) that the term promiscuous 
may imply at times what they refer to as ‘invisible’ phenotypes, observable only 
under certain conditions. In the past our laboratory has adopted the term 
promiscuity as generally applicable to proteins that show multiple partners but 
may use different strategies to bind in such a polyvalent way (18). We use 
herewith the term promiscuous in referring to a subset of antibodies where 
binding to a number of tested antigens in the same experimental conditions were 
detected, as compared to others that do not show binding.  
Despite its importance in human health and disease, the molecular basis of 
antibody multi-binding behaviour remains largely obscure. Towards this goal, it 
has been noted that some polyreactive antibodies have particularly high 
frequencies of aromatic amino acids in the CDR-H3 region (19) and high 
isoelectric points in heavy chain Fv regions. It has also been hypothesised that 
exposed hydrophobic patches are associated with so-called antibody 
promiscuity (20). Somewhat paradoxically however, a role for specific hydrogen 
bonding has also been proposed (21). Comparisons of germline versus antigen-
induced antibodies have shown that the former are more likely to be 
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polyreactive (22) and more flexible (23), which may suggest that one of the 
features of polyreactive antibodies is enhanced flexibility. In support of this, a 
structural analysis of a promiscuous antibody in the free and bound states has 
demonstrated that it adopts a different conformation when bound (24). In 
contrast however, Sethi et al. (25) have more recently shown that structurally 
diverse epitopes (the precise binding site on the antigen) bind differentially to a 
structurally common paratope (the precise binding site on the antibody), 
implying that paratope flexibility can be limited.   
Here, we compare the structural properties of ten antibodies, four of which 
showed a promiscuous phenotype in enzyme linked immunosorbent assay 
(ELISA) and six that did not show any binding to the antigens tested. Since the 
encoding sequences had quite similar characteristics, we wanted to investigate 
the nature of the promiscuous phenotype and whether the structural properties 
of the antibody recognition regions were very different in these two datasets. 
Using computational methods of Molecular Modelling, Kidera factor clustering 
and Monte Carlo conformational sampling, we identified physico-chemical 
properties of the CDR-H3 that are capable of distinguishing between the two 
phenotypes of antibody presented in this study. 
 
 
 
 
 
 
MATERIALS AND METHODS 
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Identification of antibody heavy and light chain variable region sequences 
for cloning 
The heavy and light chain variable region sequences for the ten antibodies used 
in this study are shown in Supplementary Materials Table S1. The heavy and 
light chain sequences had been selected, as part of another study on ageing, from 
datasets containing unpaired heavy and light chain variable region sequences. 
The datasets from which the sequences were selected are available at 
http://www.bcell.org.uk. As there was no information on the natural heavy-light 
chain pairings, the selected pairing was guided by known paired sequences in 
the literature (26).  
 
Synthesis of antibodies 
The chosen antibody heavy and light chain variable region nucleotide sequences 
were synthesised by Integrated DNA Technologies (Iowa, USA). The variable 
region sequences were cloned into heavy (encoding human IgG1 constant 
region) or light (encoding human kappa or lambda constant region) chain 
expression vectors using Polymerase Incomplete Primer Extension (PIPE) 
cloning as described previously (27). Plasmids were then transfected into 
Adherent FreeStyleTM 293-F cells (Life Technologies) using FuGENE HD 
(Promega) according to the manufacturer’s instructions. The transfected cells 
were maintained at 70-80% confluence at 37oC, 5% CO2 in DMEM GlutaMax 
(31966; Gibco) supplemented with 10% (v/v) fetal calf serum (FCS) (Gibco), 
penicillin (5000 U/mL, Life Technologies), streptomycin (100 µg/mL, Life 
Technologies) and hygromycin-B (50 μg/ml, Life Technologies). Antibody-
containing tissue culture supernatants were collected seven days post-
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transfection. The supernatants were centrifuged at 1000 g for 15 minutes, 
filtered (0.22μm filters, Sartorius) and stored at 4oC until use. Antibody 
concentration was determined by ELISA using a standard curve generated from 
an antibody of known concentration, as set out in Tiller et al (2008) (28) .  

ELISA 
Antibodies in tissue culture supernatant were diluted to 1μg/ml in PBS and were 
tested in triplicate against the following antigens: dsDNA (D1501, Sigma), 
lipopolysaccharide (LPS) (L7770, Sigma), insulin (91077C, SAFC Biosciences) 
and HEp-2 cell lysate (ABIN964023, Antibodies-online). Antibodies were also 
tested in wells that had been coated with PBS only. The choice of antigens was 
based on those commonly used in the literature (7, 28). 
The ELISA protocol was as set out in Tiller et al (2008) (28)  except for the assay 
development. Assays were developed by adding 50μl OPD substrate (5mg OPD 
tablet (P6912-50 TAB, Sigma) dissolved in 10ml 1X peroxide substrate buffer 
(34062, Thermo Scientific) and incubating in the dark for 30 minutes. The 
reaction was stopped using 50μl 3M HCl. The optical density was read at 492nm 
(OD492). A result was deemed positive if the mean OD492 was significantly higher 
than the background (i.e. secondary antibody only). 
 
Antibody structures 
Two structural datasets were built to analyse the distribution of CDR-H3 lengths 
in antibodies from all species and from humans, respectively. The “Non-
redundant CDR search” option in SAbDab (Structural Antibody Database; 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
accessible at <http://opig.stats.ox.ac.uk/webapps/sabdab>) (29) was used to 
include only complete CDR-H3 regions from crystal structures solved at a 
resolution of ≤ 3Å. CDR-H3 lengths were determined according to the Chothia 
definition. The PDB codes for both datasets are available in the supplementary 
material (Supplementary Materials Table S2). 
 
Antibody Modelling 
The modelling workflow is described in Fig. 1 and the steps are outlined below.  
 
[Fig. 1. Modelling workflow] 
 
Step 1: Template Search 
The search for templates was carried out using the PIGS web server (Prediction 
of ImmunoGlobulin Structure; available at <http://www.biocomputing.it/pigs>) 
(30, 31) and MOE (Molecular Operating Environment; Version 2013.08; 
Chemical Computing Group, Montreal, Quebec, Canada). Both programs are 
considered to be state of the art in antibody modelling but differ in their 
methodologies (32, 33) PIGS employs the “canonical structure” (CS) approach, 
which rests on knowledge that five out of the six CDRs adopt a limited number of 
conformations (so-called canonical structures) whose sequence determinants 
have been identified (4, 5). The exception to this, however, is the CDR-H3, whose 
sequence length and composition have so far proven too variable for complete 
CS rules to be identified (3, 6, 34-36). Indeed, matching CDR-H3 conformations 
becomes increasingly difficult for cases in which the loop is particularly long. In 
some cases, PIGS was found to perform less when CDR-H3 sequences were 
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queried, as previously pointed out (30, 31, 37). Furthermore, and most 
important in our case, PIGS does not allow the user to search for templates 
specific to one CDR region. For these reasons, we used instead the Antibody 
Homology Modelling application suite in MOE to search for a CDR-H3 specific 
template.  
 
Step 2: HMM Multiple Sequence Alignment  
The template and query sequences provide the input for Step 2: HMM Multiple 
Sequence Alignment. Heavy chain (IgH) and light chain (Igκ/Igλ) alignments are 
generated independently using isotype-specific HMM profiles developed by 
Tramontano and coworkers, as described in (31). Using this alignment method, 
gaps in the sequence are added outwards from the centre of the CDRs and 
conserved residues are always aligned. 
 
Step 3: Model Building and Selection  
Step 3 requires the combined H-L alignment from Step 2 and the template 
structures retrieved in Step 1. 200 structural models are built using the 
comparative modelling procedure in MODELLER (38) and the best model is 
selected using normalised DOPE scoring as the quality measure. Models with 
scores above -1 indicate the presence of nonnative interactions and were not 
considered. Models were visualised with Visual Molecular Dynamics (VMD; 
<http://www.ks.uiuc.edu/>) (39). 
 
Step 4: Conformational Sampling  
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In the last step, the previously selected best model is energy-minimised using the 
OPLS-AA force field (40) and then used as the starting structure for tCONCOORD 
simulations (41, 42). From this, an ensemble of 500 tCONCOORD structures is 
generated using default parameters. We used this procedure, analogously to our 
previous work (18) because this method efficiently samples the conformational 
space (see Figure S6 for root-mean square distribution) and is therefore suited 
to antibody loop sampling, otherwise very difficult to tackle with molecular 
dynamics or any other atomistic-based sampling. This method is not affected by 
convergence issues, and has been demonstrated to extract representatives of the 
structural variability of proteins on the basis of both MD simulations and 
experimental data (18). 
In essence, tCONCOORD samples alternative conformational states in-vacuo by 
fulfilling a set of geometrical constraints extracted from the initial coordinates 
and interaction types (e.g., covalent bonds, hydrogen bonds, salt bridges, or 
hydrophobic interactions).  
The tCONCOORD constraint definition is based on a statistical analysis of high-
resolution X-ray structures and includes a ‘solvation score’ measure of hydrogen 
bond stability (41). Based on this description the structure of the protein is 
rebuilt many hundreds of times, leading to an ensemble that can be analysed. 
 
Clustering analysis 
A hierarchical clustering method was employed using the hclust function in R 
(v3.2.3) and a Minkowski distance, p, of 4. Antibodies were clustered according 
to the Kidera factors of their CDR-3 region amino acids (Chothia definition). The 
Kidera factors have been derived to encode 188 physical properties of the 20 amino 
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acids using dimension reduction techniques. They consist of a 10-dimensional 
vector of  orthogonal factors for each amino acid (43).  
 
 
Secondary structure analysis 
Models were first protonated using MOE. Secondary structure predictions were 
performed with DSSP (44) and the output was recorded as follows: extended β-
strands and β-bridges as “Beta”; α-helices, 310-helices and π-helices as “Helix”; 3, 
4, and 5 turns and non-hydrogen bonded bends as “Turn”; random coil as “Coil”. 
Normalised secondary structure probabilities were calculated for the CDR-H3 
and CDR-L3 (Chothia definition). 
 
The 95% confidence intervals were calculated using a bootstrapping method 
(boot() function in R) to generate 100 randomly resampled subsets for each of 
the reference datasets. This allowed any biases resulting from dataset selection 
to be avoided. 
 
Conformational analysis 
The maximally correlated motion or MCM has been calculated for the 
tCONCOORD trajectories. This is usually expressed as a linear combination of 
principal components (PCs) derived from a principal component analysis (PCA) 
of the system trajectory. We considered here only the first 2 PCA eigenvector 
components of the trajectory as these are contributing mostly to the total 
Eigenvalue displacement (in nm2) (Supplementary Materials Fig. S3). To identify 
the CDR-3 atoms collective motion, which maximally correlate with these two 
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PCA components we extracted the projection of the CDR-3 atoms trajectory onto 
the 1st and the 2nd PCs. 
 
Models are available upon request to the authors’ e-mails:  
Julie MJ Laffy: julie.laffy@kcl.ac.uk;  
Franca Fraternali: franca.fraternali@kcl.ac.uk. 
 
 
 
 
RESULTS AND DISCUSSION 
Identification of promiscuous antibodies 
Ten antibodies were tested in an ELISA against a panel of four different antigens 
and blank, uncoated wells. It was found that the ten antibodies could be classed 
as showing one of the two following phenotypes: (i) a negative signal in all the 
ELISA wells (GF2, GF3, GF4, GF6, GF8, GF10 in Fig. 2) and (ii) a positive signal in 
all the ELISA wells (GF1, GF5, GF7, GF9 in Fig. 2). We named the antibodies 
which showed a positive signal under every ELISA condition in which they were 
tested “promiscuous”. Multiple sequence alignments of the promiscuous and 
non-promiscuous antibodies are shown in Fig. S1. 
 
[Figure 2. Promiscuous antibodies identified by ELISA] 
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We note that the promiscuous antibodies showed a positive signal even in the 
absence of antigen on the ELISA plate. The reactive nature of a promiscuous class 
of antibodies could be such that one might expect their binding to empty wells in 
addition to other antigens. Nevertheless, the promiscuous antibodies clearly 
possess a different phenotype to the non-promiscuous antibodies, which can be 
detected in this ELISA format, and are relevant to previous literature where 
these methods have been extensively used to assess 
polyreactivity/autoreactivity (7, 28, 45). We therefore investigated this 
phenotype further using computational methods. 
 
CDR-H3 loop length and sequence composition 
Numerous previous studies have shown that the CDR-H3 loop is much more 
variable in its sequence length compared to that of the remaining CDRs, and that 
this is a critical determinant of its conformation. Fig. 3 shows the distribution of 
CDR-H3 lengths of the ten antibodies investigated in this paper (pink), a human 
antibody repertoire (blue) (data from Wu et al. (46)) and antibody structures 
deposited in the PDB (orange, human; green, all species). 
 
[Figure 3: CDR-H3 length distributions] 
 
The CDR-H3 sequence length distribution of the GF antibodies analysed in this 
study were found to be longer, on average, when compared to both the human 
sequence repertoire and the PDB. Previous work has associated longer CDR-H3 
regions with antibody binding multiplicity, which may render this observation 
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significant [ref]. It should be noted however that there is no significant difference 
in length between the promiscuous and non-promiscuous GF subsets analysed 
here.  
The PDB length distributions displayed a strong preference for shorter CDR-H3 
loops. This may be due to the complications associated with structure 
determination of long, flexible regions of polypeptide. In any case, the 
discrepancy in CDR-H3 length between the GF antibodies and the PDB structures 
meant that our template search space was confined to the subset of adequate 
CDR-H3 lengths illustrated by the shaded green region in Figure 3.  
 
[Figure 3. Distributions of CDR-H3 lengths in the GF antibodies (pink), the 
human antibody repertoire (blue) and the Protein Data Bank (green and 
orange).] 
 
Kidera factors and β-sheet propensities are good indicators of GF 
promiscuity 
Attempts to classify promiscuous antibodies from sequence information alone 
have generally been unsuccessful (see review by (14)).  Although some studies 
have identified the CDR-H3 region as being accountable for the promiscuous 
nature of antibodies (47-49), this region is always critical in antigen recognition, 
regardless of promiscuous behaviour. 
 
With this in mind, we first sought to quantify the sequence-based similarities 
amongst the GF antibodies using a hierarchical clustering method (see Materials 
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and Methods) and postulated that the inclusion of implicit structural information 
might improve the quality of our clustering analysis. As such, for each of the ten 
GF antibodies, protein sequences within the CDR-H3 and -L3 loops were 
assigned Kidera factors (a set of scores, which quantify physicochemical 
properties of protein sequences (see Materials and Methods) (43).  
 
The CDR-L3 loop was considered in this analysis, in addition to the –H3 loop, 
because of its demonstrable function in conferring antibody-antigen specificity. 
The assignment of Kidera factors to the two sequence regions were combined to 
give a score for each of the ten antibodies, providing a set of scores by which to 
cluster. 
 
[Figure 4. Promiscuous (red) and non-promiscuous (blue) GF antibodies can be 
distinguished on the basis of (A) CDR-3 Kidera properties and (B) CDR-H3 β-
sheet occupancy.] 
 
Three principal clusters were defined (Fig. 4A) from this clustering procedure 
using Minkowski distance as the metric (see Materials and Methods). Of these 
clusters, two were comprised exclusively of either promiscuous or non-
promiscuous antibodies. More specifically, the largest cluster (Cluster 1) 
contained 66.7% of the total number of non-promiscuous antibodies and 0% of 
the promiscuous antibodies while Cluster 3 contained 75% of the promiscuous 
antibodies and 0% of the non-promiscuous antibodies. Cluster 2, on the other 
hand, contained a mixture of both classes (25% of promiscuous cases and 33.3% 
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of non-promiscuous cases). Promiscuous GF1 and GF7 and non-promiscuous 
GF2 and GF4 were the most rooted in their respective clusters, which suggested 
that the traits associated with either binding phenotype should be best 
represented by these antibodies. 
 
It is worth noting that similar clustering analyses were performed using simpler 
parameters to describe the CDR-3 regions, such as hydrophobicity and charge, 
but no clear separation between the two sets was observed (data not shown). It 
can therefore be concluded that Kidera Factors are a powerful means of 
incorporating general physico-chemical properties and structural information 
into a sequence-based analysis. Interestingly, in the context of blood repertoire, 
similar conclusions were reached in a study by Epstein et al. (50), which used 
Kidera factors to analyse TCR repertoires from different individuals. 
 
Enriched β-sheet content in promiscuous CDR-H3 regions 
The variable regions of each of the GF antibodies were modelled to look for 
explicit structural differences between members of the different clusters (see 
Fig. 4). In each case, the most native-like representative from a sample of 200 
models was selected (presented in Fig. 4B) (see Materials and Methods for more 
information).  
 
Intriguingly, the β-sheet content of the CDR-H3 was highly enriched in the 
promiscuous antibody models, particularly in those within Cluster 3 (Fig. 4). 
Moreover, the only promiscuous antibody not belonging to Cluster 3 (GF9) was 
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also the only one that appeared to lack the ordered β-sheet seen in the other 
cases. In fact, the CDR-H3 secondary structure of GF9 much more closely 
resembled a random coil; a feature that was shared amongst all antibodies in 
Clusters 1 and 2.  
 
The β-sheet-forming propensities (51) of residues in the CDR-H3 regions (Fig. 5) 
also reflected the results in Fig. 4. Within Cluster 3, β-sheet breakers (pink) and 
strong β-sheet breakers (red) were concentrated at the apices of the CDR-H3s 
and were largely absent from their stems, thereby permitting anti-parallel β-
sheet hydrogen bonding. The exception to this was a serine residue in GF5 
(breaker; pink), however its geometry and neighbouring environment was such 
that a hydrogen bond still formed. Contrastingly, the distributions of β-sheet 
breakers were far more scattered in members of Clusters 1 and 2. A higher 
occurrence of strong β-sheet formers (green) in the stems of Cluster 3 members 
was also noted. Once again, this observation was less relevant in GF5. To this 
point, it is perhaps worth noting that GF5 was the least deep-seated in Cluster 3 
(Fig. 4). 
 
[Figure 5. β-sheet propensities and structure of CDR-H3 residues.] 
  
Beyond β-sheet propensities, the degree of CDR-H3 collapse seemed to correlate 
well with membership to a particular cluster (Fig. 5). Cluster 1 CDR-H3 members 
were the most ‘tangled’; Cluster 2 members were comparatively taut and Cluster 
3 members were most extended (forming β-sheet structure). 
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To assess the statistical significance of this finding and to ensure that differences 
in secondary structure content were not simply a reflection of the templates used, 
Monte Carlo-based simulations were run on all GF antibodies using the 
tCONCOORD program (see Materials and Methods). CDR-H3 secondary structure 
probabilities were calculated for the GF ensembles of 500 tCONCOORD structures 
and subsequently averaged over the promiscuous and non-promiscuous sets.  
 
[Figure 6. Average secondary structure probabilities in simulation ensembles for 
(i) promiscuous and (ii) non-promiscuous antibodies.] 
 
As illustrated in Fig. 5, the CDR-H3 β-sheet content was 33.4% higher in the 
promiscuous antibodies compared to the non-promiscuous antibodies (two-
tailed P value < 0.0001) and this difference was even more pronounced when 
GF9 was excluded from the promiscuous set (data not shown). The non-
promiscuous antibodies were also predicted to have 18% more ‘turn’ secondary 
structure (defined as 3, 4, and 5 turns and non-hydrogen bonded bends) (two-
tailed P value < 0.0001).  
Predicted secondary structure occupancies were also calculated for the CDR-L3 
regions of the promiscuous and non-promiscuous antibodies however no 
significant differences were observed (Supplementary Materials Fig. S2).   
 
Key residues in the CDR-H3 of GF1 
To reduce the high dimensionality of the tCONCOORD trajectories and to identify 
the dominant molecular motions related to either promiscuous or non-
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promiscuous antibodies, principal component analysis (PCA) was applied. Two 
representative tCONCOORD trajectories were taken from each class; GF1 for the 
promiscuous subset and GF4 for the non-promiscuous subset. As mentioned 
earlier in the text, these antibodies were amongst the most deep-rooted in their 
respective clusters (Fig. 4A). Furthermore, their CDR-H3 and CDR-L3 loops were 
determined to be of approximately the same length and of very high sequence 
similarity (CDR-H3, 99%; CDR-L3, 95%). In the trajectories of both GF1 and GF4 
the dominant global motion was found to be a side-to-side ‘rocking’ of the heavy 
and light chain framework regions (Supplementary Materials Fig. S4). When the 
projection of atoms in the CDR-H3 and -L3 loops onto PC1 and PC2 were 
determined, several residues in the CDR-H3 loops of the promiscuous GF1 
antibody, but not GF4, were also found to contribute to the global motion 
accounted for by the first and second eigenvectors (Fig. 7). The CDR-L3 regions 
were found not to contribute significantly to the global motion in either the first 
or the second eigenvectors (Supplementary Materials Fig. S5).  
 
[Figure 7. Principal component analysis of CDR-H3 dynamics.] 
 
Analysis of PC1 and PC2 highlighted four particularly dynamic residues in the 
CDR-H3 of GF1: Lys100, Asp100B, His100C and Trp100E (Chothia numbering 
definition; Fig. 7A). Interestingly, these residues are concentrated at the apex of 
the CDR-H3 β-sheet (Fig. 7B). Furthermore, some of these residues contain 
features that are indicative of binding versatility. Firstly, residues such as Lys 
and Trp are often found at binding interfaces due to their ability to adapt to both 
hydrophobic and hydrophilic environments (52). Residues with a large surface 
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area (Lys, His, Trp) should also contribute favourably to binding free energies 
with antigen due to their participation in van der Waals’ interactions (4, 5, 53). 
Lastly, some residues, including Tyr and Trp, are intrinsically flexible (54); a 
property that has previously been found as characteristic of promiscuous 
residues in hub proteins (18). Such residues could sample a wider range of 
dihedral angles and adjust their fit to accommodate different antigens.   
 
Putative binding mechanisms 
We hypothesize that the advantage of a protruding β-sheet-rich CDR-H3 in the 
promiscuous antibodies lies in the inability of its residues to partake in intra-
molecular interactions. Instead, such outwardly positioned residues would be 
most effectively placed to encourage interactions with foreign molecules. In 
contrast, the lower occurrence of β-sheet in the non-promiscuous CDR-H3 loops 
would result in a higher number of ‘rigidifying’ intra-molecular CDR-H3 contacts. 
This could explain why the CDR-H3 residues in GF4 were less dynamic than their 
counterparts in GF1 despite residing in an otherwise flexible random coil (Fig. 
7).  
Beyond this, the findings presented here suggest that specific residues in the GF 
antibodies confer promiscuity, as was found in a large-scale analysis of multi-
binding proteins (18). The dominant nature of the promiscuous CDR-H3 could 
permit the exposure of local and chemically versatile neighbourhoods of amino 
acids with configurations free of the steric or structural constraints normally 
expected within the antibody-combining site. 
 
Conclusions 
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Binding promiscuity is a characteristic of many proteins and is an essential 
feature for efficient cellular communication. In the past (18) we characterised 
the essential role played by promiscuous residues at the surface of multi-binding 
proteins (hubs) and revealed an important feature the flexibility exerted by 
these residues and their enhanced motion. This plasticity can be efficiently 
exploited in supporting diversity of interaction and effective binding. Here we 
focused on another important class of proteins, antibodies, and highlighted the 
important role of physico-chemical properties of specific residues at the CDR-H3 
in conferring promiscuous behaviour to a set of antibodies tested for multiple 
binding to a small panel of antigens in-vitro.  Interestingly, we found that it is not 
the entire region of the paratope that has to exhibit flexibility to effectively 
modulate promiscuous binding, but this comes at a compromise between the β-
sheet content of the CDR-H3 that can hold in place and protrude out of the 
antibody combining-site, thereby ‘offering’ to the epitope the crucially binding 
effective residues that can exert their plastic role and explore multiple binding 
conditions. In analogy with the previous findings, the promiscuity is relegated to 
only few versatile and intrinsically flexible residues. These are concentrated at 
the apex of the CDR-H3 β-sheet and found to contribute to the global motion 
accounted for by the first and second eigenvectors of the variable framework 
region. The observed properties were crucially different from the ones measured 
for a comparable class of antibodies that showed no binding preferences in the 
same tested conditions. 
The findings presented here can have important applications in the design of 
specific antibodies devoid of promiscuous behaviour, as it is well known that in 
many circumstances antibodies elicited towards a specific antigen are found to 
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bind to structurally unrelated epitopes (55). Additionally, the role of specific 
physicochemical determinants in promiscuous protein activities could pave the 
way to alternative approaches to directed evolution of novel protein functions 
(56).  
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Figure 1. Modelling workflow.  The pipeline takes the Fv regions of partner heavy 
and light chain sequences as input in Step 1 (cyan). The search for templates is 
conducted using the PIGS web server and the Antibody Homology suite in MOE. 
A CDR-H3-specific template is extracted from the MOE search. The PIGS “Same 
antibody” method is used to search for a template whose heavy (H) and light (L) 
chains are the best combined match for the query H and L sequences. If the 
sequence identity match of either chain in the PIGS template is below 70%, an 
additional chain-specific template is selected using the alternative “Best H and L 
chain” PIGS strategy. Together with the query H and L sequences, the selected 
template sequences are used as input in Step 2 (green). Heavy chain (IgH) and 
light chain (Igκ/Igλ) alignments are generated independently using isotype-
specific HMM profiles developed by Tramontano and coworkers, as first 
described in (57). The combined alignment and the template structures 
identified in Step 1 are used in Step 3 (orange). 200 models are built using the 
comparative modelling procedure in MODELLER and the best model is selected 
using normalised DOPE scoring as the quality measure. In the last step (blue), 
the model is used as the starting structure for tCONCOORD simulations. An 
ensemble of 500 tCONCOORD structures is generated using default parameters. 
Pink, input/output; solid red arrow, proceed to the next step in the scheme; 
dashed red arrow, proceed to a non-immediate step in the scheme.  
  
Figure 2. Promiscuous antibodies identified by ELISA.  Ten candidate 
promiscuous antibodies were screened for binding against DNA, LPS, insulin and 
HEp2. Four of these antibodies (GF1, GF5, GF7 and GF9) gave positive results in 
all wells. The remaining six antibodies (GF2, GF3, GF4, GF6, GF8, GF10) produced 
only negative results. All wells contained phosphate-buffered saline (PBS) 
solution with Tween (a non-ionic detergent) acting as a blocking agent. The 
colour key represents the well coating used. No Ab, no antibody; No Ag, no 
antigen.  
  
Figure 3. CDR-H3 length distributions.  Green, antibody PDB structures from all 
species; Orange, Human antibody PDB structures. Blue, Human sequences from 
the peripheral blood (data from Wu et al. (46)); Pink, selected GF sequences. The 
shaded green area represents the range of templates’ CDR-H3 lengths used in the 
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structural modelling of GF antibodies. A CDR-H3 length cutoff threshold of more 
than 40 amino acids was applied to the PDB set containing all species.   
 
Figure 4. Promiscuous (red) and non-promiscuous (blue) GF antibodies can be 
distinguished on the basis of (A) CDR-3 Kidera properties and (B) CDR-H3 β-
sheet occupancy.  (A) Each node on the tree is a GF antibody represented by the 
Kidera factors of its CDR-3 regions. Data were clustered using the Minkowski 
metric with a distance p of 4.  (B) Structural Fv models of the GF antibodies. The 
CDR-3 regions on the heavy and light chains are highlighted in red and 
blue for promiscuous and non-promiscuous cases, respectively.  
  
Figure 5. β-sheet propensities and structure of CDR-H3 residues.  Backbone 
representation of the CDR-H3 with amino acids coloured according to their 
propensity to form β-sheet (51): green, strong formers (V,I,M); blue, 
formers (F,Y,C,T,W,L,Q); yellow, indifferent (R,G,A,D); pink, breakers (H,S,K,N,P); 
red, strong breakers (E). Clusters were defined according to the result in Fig. 4. 
GF labels in red denote promiscuous CDR-H3s; blue labels denote non-
promiscuous CDR-H3s.  
  
Figure 6. Average secondary structure probabilities in simulation ensembles for 
i) promiscuous and ii) non-promiscuous CDR-H3 regions. Predictions were 
calculated using DSSP. Each antibody is represented by a conformational 
ensemble of 500 tCONCOORD structures, such that the total number of 
structures in i) is 2000 (4 antibodies) and in ii) is 3000 (6 antibodies). The error 
bars represent the confidence intervals at the 95% level, estimated using 100 
runs of bootstrap resampling. 
 
 Figure 7. Principal component analysis of CDR-H3 dynamics. (A) The 
contribution of each atom in the CDR-H3 loop of GF1 (red) and GF4 (blue) to the 
first and second eigenvectors measured in nm2. (B) The residues whose atoms 
contributed most significantly to the respective PCs in GF1 were 
labelled in (A) and mapped onto the GF1 model. Corresponding residues were 
mapped onto the GF4 model for reference.  
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Figure S1. Multiple sequence alignments of (A) the heavy chain and (B) the light 
chain sequences of the promiscuous and non-promiscuous antibodies. Sequences 
were aligned using the Simple MSA option in T-Coffee (58, 59). 
  
Figure S2. Average secondary structure probabilities in simulation ensembles for 
i) promiscuous and ii) non-promiscuous CDR-L3 regions. Predictions were 
calculated using DSSP. Each antibody is represented by a conformational 
ensemble of 500 tCONCOORD structures, such that the total number of 
structures in i) is 2000 (4 antibodies) and in ii) is 3000 (6 antibodies).  
  
Figure S3. Eigenvalue spectrum for GF1 (red) and GF4 (blue). 
The contribution (in nm2) of the first six eigenvectors to the total global motion 
of the tCONCOORD ensembles  (see Materials and Methods) of GF1 and GF4.   
  
Figure S4. Porcupine representation of the first and second principal 
components of the promiscuous and non-promiscuous tCONCOORD 
ensembles. The red spikes represent the direction and relative magnitude of the 
motion of each Cα atom along the first and second principal components.   
  
Figure S5. Principal component analysis of CDR-L3 dynamics. The contribution of 
each atom in the CDR-L3 loop of GF1 (red) and GF4 (blue) to the first and second 
eigenvectors measured in nm2.  
 
Figure S6. Root mean square deviation of CDR-H3 loops from tCONCOORD 
trajectories. The spatial distribution of the CDR-H3 loops from an ensemble of 
500 structures was measured for the promiscuous (red) and non-promiscuous 
(blue) sets of antibodies.  
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 
  
ID  IGHV  IGHD  IGHJ  CDR-H3  IGLV  IGLJ  CDR-L3  
GF1  ,*+9 ,*+' ,*+- $599*66.:'+$:<'/ ,*.9 ,*.- 44<11:357 
GF2  ,*+9 ,*+' ,*+- $5*5<5'<613$&9)'< ,*/9 ,*/- 66<$*611/59 
GF3  ,*+9 ,*+' ,*+- $.':(.<&6**6&4<'< ,*.9 ,*.- 44<<6735,7 
GF4  ,*+9 ,*+' ,*+- $.(</.*5'*<1<<)'< ,*/9 ,*/- 66<$*611/( 
GF5  ,*+9 ,*+' ,*+- $.$6/95<)':/)1)'< ,*.9 ,*.- 4.<16$33)7 
GF6  ,*+9 ,*+' ,*+- $5$<15&6**6&<(+(77/7*)'< ,*/9 ,*/- $$:''6/6*36:9 
GF7  ,*+9 ,*+' ,*+- $5'09/(:6<<<<*0'9 ,*.9' ,*.- 44$16)3:7 
GF8  ,*+9 ,*+' ,*+- $63736*66$5<<<<<*0'9 ,*/9 ,*/- 0,:+66$&9 
GF9  ,*+9 ,*+' ,*+- $5*3+5<*'<**<<<<<*0'9 ,*.9' ,*.- 44$16)3,7 
GF10  ,*+9 ,*+' ,*+- $5(*&**'&<6<<<<<<0'9 ,*.9 ,*.- 49<16$3397 
Table S1. Ten antibody heavy and light chain sequences selected for cloning based on 
the difference in frequency of their properties. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
658 Ig structures from all species in the PDB  
1iqd 1iqw 4g6f 3fo2 4kvc 3grw 4↵y 3ggw 3zkq 1pz5 1igm 4jr9 4i77 3ifl 1u0q 
1nlb 1za6 1q9w 3giz 3fo9 1zan 3kym 3mlr 2osl 4aeh 1opg 1s3k 3k7u 1yej 3inu 
4hpy 1dfb 3bn9 1ndg 4hk0 1lo4 1egj 3ux9 3vg9 1sy6 2otu 3eak 2b1h 4dtg 3lrs 
3phq 2g5b 3q6g 3sqo 2w60 3tcl 3zkm 1psk 2h9g 1kiq 1mam 4hs8 3m8o 35c8 
2vxv 2hwz 3tnn 3utz 3ezj 7fab 1yjd 3efd 4m48 1rih 2cmr 3g5y 1sbs 3k80 3r1g 
4jb9 1h8s 3t65 4jo4 4hkx 2zch 3eot 3pp4 1fn4 1ikf 3b9v 1qd0 1fvd 1gig 3r06 
1nak 1cly 2qqn 3okd 4ene 2c1p 4hie 2xzc 3go1 2e27 3hc3 43c9 1dl7 4ht1 4at6 
3qhz 1uj3 2nr6 1cz8 3t3p 4hc1 4hzl 3l95 3gjf 4jzn 1c5d 4dkf 2adg 2fb4 3auv 
1ob1 1yy8 3eba 4ky1 2y6s 1ghf 1f3d 1l7t 4aei 1hil 1a2y 2eh7 4hjj 1igc 2or9 
1u6a 3u30 1rhh 1wej 2aju 3ujt 4b41 3nh7 1f8t 2op4 1tqb 1t2j 2x89 3o2d 4g5z 
3vfg 4jqi 1ay1 2hfg 1mim 2gsi 4dqo 4fql 1jpt 1mvf 1c5c 4idl 3mck 1nsn 3cfb 
4dvb 4jo1 3qxt 1clo 4hxa 3liz 2xzq 3mlw 3tpk 3fzu 1uz8 4fqi 1kcr 1gpo 1ic7 
1bz7 4jam 1kb5 4laj 4k3e 2f5a 4↵v 2zpk 2vl5 4amk 2vxq 2fat 1rz7 1mex 3bkj 
1ors 1a6v 1sm3 3i02 4gsd 3fn0 3s96 1for 1fh5 3mbx 3pnw 3vi3 1dvf 1ai1 1p7k 
1ri8 1n4x 3zkx 4fqq 1kxt 4fz8 2agj 1jfq 3juy 1kxq 2yk1 3g04 3eyf 3b9k 1mnu 
3i9g 3u9p 2bdn 1eap 1flr 1mh5 3r0m 4k3j 3qeh 2qqk 1tzi 2q8b 4gag 3dv6 3d85 
3gm0 2a9m 3g9a 3s35 4h0i 4jha 2d7t 2ipu 4eig 1mj8 3u7y 4kuc 2z92 3upc 
2w9d 1rur 1aqk 1fai 3qpq 3gkw 3sob 2vq1 3na9 2g75 3u1s 1q72 1zea 1frg 1kcv 
1ol0 3se8 1xgy 2brr 1igf 4jm4 2o5x 3ifp 4hwe 1jgl 1rjl 1plg 3vw3 1dn0 2jel 3e8u 
3lh2 1mqk 3idx 4gmt 2xt1 2g60 3i75 1nj9 1etz 2r0l 3tnm 2hrp 4gq9 1mju 3idg 
3d9a 1dzb 1h8n 4jg1 4eow 4jn2 4hs6 4krn 2j4w 2xkn 3qsk 3o6k 3mcl 4fqj 3pgf 
2aab 2hh0 3k74 2v7h 3sdy 3b2u 3ijh 3ujj 3ojd 1nbv 1um5 1j05 4hix 1fl5 3uc0 
3lex 12e9 1e6o 2xa8 1ind 3u2s 3ls5 1ct8 1jgu 1t4k 1ce1 1jn6 3v6o 1ejo 2uzi 4gft 
1jrh 3dvg 3k2u 3mxw 3skj 1n0x 1keg 4j6r 4dka 4leo 2wzp 3iet 3cvi 1qfu 1il1 
1nc2 3uji 2vxs 2arj 4fze 4kph 4krm 1mfa 1zv5 1i7z 4ers 3oaz 3ln9 1yc7 4lst 4d9l 
1uwe 2xqb 3↵d 1fj1 4f33 1aif 4aq1 3cx5 1pg7 1vge 2dqu 1f4w 4jpk 1kel 4fnl 
4gxv 2hmi 3hnt 3ra7 3u0t 4k2u 1cic 3hi6 4jpw 1c12 4m43 1igt 1t3f 3qot 3eo9 
2jb5 4k3d 3i2c 4gw4 3so3 3cfd 2xa3 4g3y 4fhb 3dur 2ih3 2bmk 1zvy 4h0h 2aep 
2pcp 3ks0 2p45 2cju 4krp 4k7p 1kfa 3rvv 1nl0 2a6i 1ngz 3eo0 1rmf 3stb 4h20 
1cr9 3qg6 1ztx 1dee 3bky 3oz9 2zkh 1a6t 1kxv 1fns 2ck0 3h42 3kr3 1hi6 2x1q 
3ncj 3o0r 1fe8 1qkz 1ad9 1mvu 1mcp 1q0x 2qhr 3ma9 1tzh 1lk3 2vyr 1yee 1ap2 
1baf 3umt 3rkd 1y0l 1f58 1mlb 1dqd 4ebq 4ag4 3uls 2uyl 3h3b 2g2r 1sjv 2yc1 
3sge 1a4j 1dlf 3cmo 4b5e 3esu 2ok0 4hxb 1ndm 4imk 3cfi 4lsu 1osp 3nfs 1a3r 
4lkc 1hcv 3mo1 2adf 2iq9 2wuc 8fab 4jy5 2gcy 1mrd 1f2x 1e4x 3qyc 1dsf 3c08 
3v0w 2h1p 1g9m 2v7n 3ldb 3clf 1jhl 1eo8 1bj1 1fsk 1ncw 3hc4 1kcu 2uud 3s34 
Table S2. PDB codes for all species and Human datasets. 
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1igj 1uwx 2ddq 1lo0 3gk8 4hpo 4f57 1dqq 2j88 3gkz 2xra 3mly 1x9q 4j8r 4hlz 
4hcr 3se9 3ntc 3hr5 3o2v 3qcu 3qpx 3q3g 3dif 3hzm 4m61 2hkf 3dsf 1l7i 3lmj 
2qsc 1bfv 1t66 4dcq 1ohq 4i9w 4d9q 3v0a 1ngy 4ej1 2ypv 4hbc 3v6f 3u0w 1nld 
3esv 4hfw 4jy6 3p9w 2fx7 3h0t 2vxt 1h0d 2r8s 4lmq 1ktr 3ifo 1ggc 2xtj 1dql 
4dgy 4g6m 2ny1 2ghw 1emt 3qwo 2gki 1d5i 1ibg 4lsp 3gi9 2x1o 3uyp 3k1k 
2xqy 3mj8 1uyw 4fqc 3kdm 3nzh 3nps 1xiw 1i9j 2xwt 3v4u 1c1e 4h88 2oz4 
3p0y 1jv5 1gaf 3l5y 3g6a 1wt5 4m1d 1fgn 2r56 1p2c 1oaq 3nz8 1dbb 1p4b 3u6r 
1nmb 4jdv 4fq2 3dgg 3ghe 3gnm 1seq 3n9g 2v17 2fbj 2x1p 1bln 1nfd 4al8 1sjx 
1ynl 1h3p 1iai 1yqv 2p4a 4jpi 1w72 1nca 2ai0 3gbn 1t2q 3qq9 2aj3 1hq4  
 
248 Ig structures from the Human PDB  
1iqd 3u0w 1it9 1n0x 4g6f 4j6r 4fqq 1uwe 3lh2 3grw 2xra 3mbx 3hi6 3hc4 3mlw 
2vxs 3fzu 4fqi 3s34 4jpi 1za6 3giz 4gw4 1i7z 3kym 4jam 3mlr 4hpo 2osl 4f57 
1opg 2f5a 1s3k 3inu 4hpy 1dfb 1t2j 4d9l 1ad0 2xqb 3bn9 3mly 1x9q 1rz7 4imk 
3aaz 3ux9 4hcr 3se9 3ntc 4gsd 3o2v 3fn0 2b1h 4dtg 3lrs 1vge 3qpx 3dvg 1fh5 
3qcu 3tcl 3dif 3zkm 4gxv 3upc 1l7i 3nps 3lmj 4ky1 2qsc 3u0t 4fnl 4fz8 3r1g 2agj 
3juy 2vxv 1ohq 3tnn 4jpw 1y0l 1ngy 7fab 3g04 3eyf 3qot 3eo9 2jb5 3fo2 4fql 
4hfw 2fx7 4k7p 3h0t 1h0d 4lmq 4g3y 2h9g 3uji 2xtj 4jb9 3tnm 3sqo 1igm 1dql 
2qqk 3qeh 3p9w 4dgy 4g6m 2ny1 3d85 2xzc 2a9m 4krp 4hkx 4fze 4dkf 3s35 
1ikf 1d5i 4jha 2d7t 3b9v 1fvd 3u7y 1ngz 4lsp 3idx 1aqk 4g6a 3gkw 3h42 2qqn 
3sob 3na9 2g75 3u1s 3bky 2zkh 4jy6 1ol0 4fqc 4hie 3kdm 3nzh 3qpq 3go1 4hs8 
3kr3 3hc3 2xwt 2ghw 4jm4 2o5x 3se8 3uls 1uj3 4hwe 3ma9 3ncj 1dn0 3p0y 
1jv5 1gaf 2vyr 4ers 3l5y 3g6a 1wt5 3gjf 4jzn 4m1d 4lst 2aj3 1nl0 2r56 3m8o 
3dgg 2hfg 2fb4 3auv 2cmr 3so3 1yy8 3oaz 1dee 3u6r 1cly 3idg 2eiz 4jdv 4fq2 
3qhz 1bvk 4eow 1ad9 2yc1 4hjj 3ghe 4hs6 3n9g 4al8 4i77 3mcl 3pgf 1u6a 3u30 
1rhh 2hh0 3t2n 3sdy 2uzi 3b2u 3nh7 4lsu 3ujj 3nfs 4d9q 4lkc 1fl5 2x89 3mo1 
2yk1 2xa8 3u2s 4g5z 1w72 2wuc 8fab 4jy5 4fqj 3gbn 2vxq 1mim 1t3f 3qyc 4dqo 
3c08 3qq9 1jpt 1g9m 1c5c 3k2u 3mxw 3skj 4hk0  
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